By indication / Pan-cancer / multiple tumour types
Pan-cancer / multiple tumour types
12 imaging agents and 9 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.
Imaging
| Agent | Isotope | Stage | Syntheses |
|---|---|---|---|
| [18F]FDG | F-18 | Approved | 164 |
| [68Ga]Ga-FAPI-46 paired with [177Lu]Lu-FAPI-46 | Ga-68 | Clinical research | 77 |
| [68Ga]Ga-FAPI-04 paired with [177Lu]Lu-FAPI-04 | Ga-68 | — | 47 |
| [18F]FAPI-74 | F-18 | — | 11 |
| [18F]FSPG | F-18 | Clinical research | 9 |
| [68Ga]Ga-OncoFAP-DOTAGA paired with [177Lu]Lu-OncoFAP-DOTAGA | Ga-68 | Research | 4 |
| [18F]FTYR | F-18 | Research | 3 |
| [18F]fluoroacetate | F-18 | — | 2 |
| 10-[11C]methoxy-20(S)-camptothecin | C-11 | preclinical | 1 |
| [11C]YM155 | C-11 | — | 1 |
| [18F]AlF-OncoFAP | F-18 | — | |
| [18F]L-Glutamic | F-18 | investigational |
Therapy
| Agent | Isotope | Stage | Syntheses |
|---|---|---|---|
| [90Y]Y-pentixather | Y-90 | — | 9 |
| [177Lu]Lu-NeoB | Lu-177 | phase I/IIa clinical trial (first-in-human) | 2 |
| [225Ac]Ac-DOTA-hu3F8 | Ac-225 | preclinical | 2 |
| [90Y]Y-90-FF-21101 | Y-90 | phase I/II clinical trial | 2 |
| [177Lu]Lu-AKIR001 | Lu-177 | phase 1 clinical trial | 2 |
| [89Zr]PEG-Nb159 paired with [177Lu]Lu-PEG-Nb159 | Zr-89 | Reported once | 1 |
| [68Ga]DOTA-FD1 paired with [177Lu]Lu-DOTA-FD1 | Ga-68 | Reported once | 1 |
| [177Lu]Lu-DOTA-MI-exendin-4 | Lu-177 | Reported once | 1 |
| [177Lu]Lu-OncoFAP paired with [68Ga]Ga-OncoFAP | Lu-177 | preclinical |
Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region — tell us what you need.
Get in touch